RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
The conversation discusses the confusion over low testosterone potentially causing hair loss, with users sharing personal experiences and knowledge about hair loss treatments like Finasteride. Some users suggest that hair follicle sensitivity to DHT, not testosterone levels, is the key factor in balding, and others discuss the side effects of hair loss medications.
A 57-year-old man with severe hair loss since age 14 tried various hair loss treatments over two years, including finasteride, dutasteride, minoxidil, and supplements, with some minor regrowth. He also experimented with topical treatments and microneedling, but results were not cosmetically significant.
Dutasteride is unlikely to worsen hair loss; shedding is often temporary. Other factors like inconsistent use, placebo effect, or additional treatments may influence perceived results.
A new Latanoprost-based formula used by Hollywood celebrities to treat hair loss, with the formula containing minoxidil, tretinoin, melatonin, azelaic acid, zinc thymulin, vitamin B6, sandalore and methyl vanillate. It also mentions the potential of offering a combined sublingual minoxidil/oral dutasteride option in the future.
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
There have been no new effective hair loss treatments since finasteride, despite technological advancements. Current treatments include finasteride, minoxidil, and RU58841, with ongoing challenges and potential future solutions in research.
Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.
Dutasteride takes 1-3 months to affect scalp DHT levels, not just a week. The prostate absorbs Dutasteride faster than the scalp due to different vascular networks and enzyme densities.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
NMN shows promise in promoting hair growth by reducing oxidative stress and weakening androgens. It may be a beneficial addition to hair loss treatments like Minoxidil and Finasteride.
Topical finasteride results in plasma levels 100 times lower than oral finasteride, potentially reducing systemic side effects. Users report similar efficacy with fewer side effects, suggesting a preference for topical application.
Hair loss treatments, including microneedling, minoxidil, finasteride and RU58841; the efficacy of these treatments; criticisms of Kevin Mann's content related to his selective data presentation and biases towards certain treatments; and other topics such as DHT being labeled a "trash hormone" and critiques of other hairloss YouTubers.
The conversation discusses promising hair cloning research seeking commercialization partners. Cultured hairs formed with pigment, indicating positive progress.
Hair loss can be treated by correcting glucose metabolism in hair follicles and using equol as a safer DHT blocker. Production of these treatments is starting soon, and a Discord channel is available for more information.
Hair loss therapies focusing on hair follicle sugar metabolism and aldose reductase. Potential treatments include magnesium supplements, avoiding high glycemic index foods, and antioxidants.
IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.
The conversation discusses using topical cetirizine as a treatment for androgenetic alopecia (hair loss). Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
The conversation is about a user feeling hopeless due to hair loss despite using finasteride, dutasteride, and OM for over a year. Responses suggest therapy, self-improvement, and changing perspectives on appearance.
Microneedling with 0.6 mm needles combined with 5% minoxidil is more effective for hair count and thickness than minoxidil alone or with 1.2 mm needles. Biweekly microneedling at 0.6 mm depth is recommended for better results in treating androgenetic alopecia.
A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
TGF-B affects hair growth, both causing stem cell division and death depending on amounts. Amplifica's treatment injects Scube3 to increase TGF-B for hair growth.
Person 1, with slow hair loss, might need less finasteride than Person 2, who is balding rapidly. The suggested doses are 0.25 mg finasteride three times a week for Person 1 and 1 mg daily for Person 2.
Natural treatments for hair loss, specifically peppermint oil and rosemary oil; how they can be used as a supplementary or alternative treatment to pharmaceuticals such as finasteride and minoxidil; and the personal experience of the user Divallo, who has seen an increase in density and thickness after using these oils for around 2.5 years. The post also touches on the potential antifungal properties of the oils and their effects on cutaneous blood flow.
Psoriasis shampoo with salicylic acid can improve scalp health and hair quality better than Nizoral. It helps create a cleaner environment for hair growth, especially when using treatments like finasteride.
Taking dutasteride daily at higher doses results in more effective DHT suppression compared to every other day dosing, due to its dose-dependent nature and long half-life. Even at lower doses, dutasteride is more effective than finasteride for hair loss.
AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.